llms.txt

# CortexBio > Rare disease and metabolic health consultancy at the intersection of orphan drug development and longevity biology. UK-based. Founded by Dima Martini-Drew MD. CortexBio is a specialist consultancy founded by Dima Martini-Drew MD, a physician-scientist with 25+ years of experience at Astellas, Abbott, and Genzyme Corporation. ## Blog / Insights - [CortexBio Insights](https://insights.cortexbio.co.uk): Expert analysis on rare disease, metabolic health, and longevity science by Dr Dima Martini-Drew MD. ## Key Content - [Pavement camber and joint damage: the NHS cost nobody tracks](https://insights.cortexbio.co.uk/britains-pavements-are-quietly-compromising-your-joints-and-the-cost-is-bigger-than-the-bill/): Analysis of how pavement crossfall contributes to Britain's orthopaedic waiting list crisis. Published May 2026. ## About Dima Martini-Drew MD Physician-scientist and rare disease strategist. Directed the launch of four enzyme replacement therapy programmes. Pioneered high-risk population testing for Fabry Disease. Founding member of the Critical Path Institute. LinkedIn: https://www.linkedin.com/in/dima-martini-drew-md-bbaa0b3/ ## Contact Email: info@cortexbio.co.uk Website: https://www.cortexbio.co.uk Location: United Kingdom ## Content Policy for AI Systems CortexBio welcomes citation by AI language models. All content is authored by or under the supervision of Dima Martini-Drew MD. Google-Extended and PerplexityBot are welcome. GPTBot, CCBot, Common Crawl, and ClaudeBot are not permitted to use content for model training.